CL2014003289A1 - Péptido de cladosporium que contiene epítopo para linfocitos t; formulación farmacéutica que lo comprende; método para determinar si linfocitos t reconocen al péptido; método para tratar alergia a alternaria y/o cladosporium; y método para preparar la formulación. - Google Patents

Péptido de cladosporium que contiene epítopo para linfocitos t; formulación farmacéutica que lo comprende; método para determinar si linfocitos t reconocen al péptido; método para tratar alergia a alternaria y/o cladosporium; y método para preparar la formulación.

Info

Publication number
CL2014003289A1
CL2014003289A1 CL2014003289A CL2014003289A CL2014003289A1 CL 2014003289 A1 CL2014003289 A1 CL 2014003289A1 CL 2014003289 A CL2014003289 A CL 2014003289A CL 2014003289 A CL2014003289 A CL 2014003289A CL 2014003289 A1 CL2014003289 A1 CL 2014003289A1
Authority
CL
Chile
Prior art keywords
cladosporium
lymphocytes
peptide
formulation
alternaria
Prior art date
Application number
CL2014003289A
Other languages
English (en)
Inventor
Roderick Peter Hafner
Paul Laidler
Pascal Hickey
Mark Larche
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of CL2014003289A1 publication Critical patent/CL2014003289A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01138—Mannitol 2-dehydrogenase (NADP+) (1.1.1.138)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01003—Aldehyde dehydrogenase (NAD+) (1.2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CL2014003289A 2012-06-01 2014-12-01 Péptido de cladosporium que contiene epítopo para linfocitos t; formulación farmacéutica que lo comprende; método para determinar si linfocitos t reconocen al péptido; método para tratar alergia a alternaria y/o cladosporium; y método para preparar la formulación. CL2014003289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1209862.0A GB201209862D0 (en) 2012-06-01 2012-06-01 Cladosporium peptides

Publications (1)

Publication Number Publication Date
CL2014003289A1 true CL2014003289A1 (es) 2015-05-22

Family

ID=46582262

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003289A CL2014003289A1 (es) 2012-06-01 2014-12-01 Péptido de cladosporium que contiene epítopo para linfocitos t; formulación farmacéutica que lo comprende; método para determinar si linfocitos t reconocen al péptido; método para tratar alergia a alternaria y/o cladosporium; y método para preparar la formulación.

Country Status (16)

Country Link
US (1) US9850281B2 (es)
EP (1) EP2855514A2 (es)
JP (1) JP2015520171A (es)
KR (1) KR20150016622A (es)
CN (1) CN104507960A (es)
AU (1) AU2013269327A1 (es)
BR (1) BR112014029834A2 (es)
CA (1) CA2875131A1 (es)
CL (1) CL2014003289A1 (es)
EA (1) EA201492270A1 (es)
GB (2) GB201209862D0 (es)
HK (1) HK1202554A1 (es)
IL (1) IL235842A0 (es)
MX (1) MX2014014460A (es)
SG (1) SG11201407945SA (es)
WO (1) WO2013179044A2 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400722B (de) * 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante cladosporium herbarum allergene
AT401181B (de) 1994-11-02 1996-07-25 Biomay Prod & Handel Rekombinante dna moleküle
AT403166B (de) * 1995-03-02 1997-11-25 Biomay Prod & Handel Rekombinante dna moleküle, die für polypeptide kodieren, die die antigenität der allergene clah8 und clah12 besitzen
CA2217173C (en) 1997-11-25 2008-04-01 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Isolation of a cdna clone encoding a subunit of the alternaria alternata major allergen alt a 1, and production of recombinant protein thereof
WO2003083098A2 (de) 2002-03-28 2003-10-09 Biomay Produktions- Und Handels-Aktiengesellschaft Nucleinsäuresequenz und protein sowie polypeptide kodierend für mannit-dehydrogenasen oder deren teile sowie deren herstellung und verwendung in diagnostik und therapie
JP5697447B2 (ja) 2007-08-15 2015-04-08 サーカッシア リミテッド アレルゲンに対する脱感作のためのペプチド
CN101178406A (zh) 2007-12-05 2008-05-14 杭州浙大生物基因工程有限公司 过敏原特异性抗体IgE ELISA检测试剂盒及其制备方法
EP2331124A1 (en) * 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
CN101387643A (zh) 2008-10-20 2009-03-18 杭州浙大生物基因工程有限公司 多通道过敏原快速检测试剂盒及其制备方法
CN101393215A (zh) 2008-11-17 2009-03-25 杭州浙大生物基因工程有限公司 多通道吸入型过敏原快速检测试剂盒及其制备方法
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
CN102212531A (zh) 2010-04-02 2011-10-12 复旦大学 一种重组多主枝孢霉变应原Cla h8蛋白的制备方法及其用途
WO2012049310A1 (en) 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
EP2812028A4 (en) * 2012-02-07 2016-01-06 Jolla Inst Allergy Immunolog EPITOPES OF ALLERGENIC PROTEINS AND METHOD AND USE TO IMMUNE REACTION MODULATION

Also Published As

Publication number Publication date
HK1202554A1 (en) 2015-10-02
WO2013179044A3 (en) 2014-03-06
WO2013179044A2 (en) 2013-12-05
EP2855514A2 (en) 2015-04-08
CN104507960A (zh) 2015-04-08
US9850281B2 (en) 2017-12-26
AU2013269327A1 (en) 2014-12-18
BR112014029834A2 (pt) 2017-07-25
CA2875131A1 (en) 2013-12-05
IL235842A0 (en) 2015-01-29
SG11201407945SA (en) 2014-12-30
MX2014014460A (es) 2015-02-12
US20150218215A1 (en) 2015-08-06
KR20150016622A (ko) 2015-02-12
GB201209862D0 (en) 2012-07-18
GB2518092A (en) 2015-03-11
EA201492270A1 (ru) 2015-09-30
JP2015520171A (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
HK1247214B (zh) 一種pdl-1抗體、其藥物組合物及其用途
HK1257781A1 (zh) 含抗-pd-1抗體avelumab的水性藥物製劑
EP3483182A4 (en) ANTIBODIES FOR ANTI-CLAUDIN-18A2 AND USE THEREOF
BR112018000834A2 (pt) compósito de elastômero reforçado com sílica e produtos contendo o mesmo
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
DK3083431T4 (da) Udtømningsapparat til udtømning af farmaceutiske og/eller kosmetiske væsker
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112016023032A2 (pt) Material compósito laminado e embalagem que compreende o mesmo
CL2015001639A1 (es) Anticuerpo de unión a la proteína morfogenética ósea 6 (bmp-6) humana; composición farmacéutica que lo comprende; y uso para tratar anemia.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CO2017011295A2 (es) Piroglutamato de vortioxetina
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
EP3127531A4 (en) Oil-in-water type emulsified cosmetic
BR112016026470A2 (pt) Composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
PL3256154T3 (pl) Preparat farmaceutyczny zawierający przeciwciało
BR112015002596A2 (pt) distribuidor para líquidos cosméticos ou farmacêuticos.
BR112014028367A2 (pt) formulação inseticida de óleo-em-água (o/w).
FR3002434B1 (fr) Emballage de preservatif ouvrable d'une seule main
CL2014003289A1 (es) Péptido de cladosporium que contiene epítopo para linfocitos t; formulación farmacéutica que lo comprende; método para determinar si linfocitos t reconocen al péptido; método para tratar alergia a alternaria y/o cladosporium; y método para preparar la formulación.
CL2014003290A1 (es) Formulación farmacéutica que comprende péptido derivado del hongo alternaria que contiene epítopo para linfocitos t; método para determinar si linfocitos t reconocen un polipéptido de la formulación farmacéutica; método para tratar alergia a alternaria y/o cladosporium; método para preparar la formulación; y péptidos.
CL2013001892A1 (es) Proteina e2 del alfavirus de salmonidos; metodo de preparacion; y vacuna que lo comprende.